Home / Companies / News / Cipla looks to invest more in mRNA tech; holds discussions with firms

Cipla looks to invest more in mRNA tech; holds discussions with firms

Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the commercial growth engines

Premium

India’s indigenous mRNA vaccine from Pune-based Gennova Biopharmaceuticals is also in the last leg of development and commercialisation as the firm awaits a nod from the drug regulator to launch the vaccine here

Sohini Das Mumbai

3 min read Last Updated : May 12 2022 | 6:01 AM IST

After taking the lead in having a strong Covid-19 portfolio during the pandemic, Cipla is now gearing up for the next stage of growth in terms of innovation and expanding its presence in newer domains. The Mumbai-based firm has held discussions with mRNA technology companies over the last eight months as it looks to invest in a few of them.

“We have been talking to mRNA technology owners in the past eight months. We are at a stage when we might invest in a few mRNA companies. The best way is to invest in such technology companies and then grow

Topics : Cipla World Health Organisation Biological E Coronavirus Vaccine

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in